StockNow
Calendar
Log in
U.S. Markets

Bristol Myers Squibb (BMY) announces positive topline results from the Phase 3 EXCALIBER-RRMM study, evaluating ZENBEXUS in combination with daratumumab and dexamethasone in patients with multiple myeloma, as early as first relapse

StockNow breaking-news AI analysis

Bristol Myers Squibb announced positive topline results for a Phase 3 combination study in multiple myeloma, but the supplied record provides no data or detailed findings.

1 stocks
BMYBristol-Myers Squibb Co.$59.68Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Fed

Fed’s Waller (voter) says more rate hikes are likely needed to tame inflation, but there is flexibility over the pace and hikes do not need to be consecutive

Geopolitics

Reports of explosions heard and fires visible in Riyadh, Saudi Arabia, IRGC-linked Iraqi militia media Sabereen News reports

Geopolitics

Iranian supreme leader’s adviser says the Strait of Hormuz will not reopen until outstanding issues are resolved, Al Jazeera reports; Iran will take any measures necessary to strengthen the country